UTHR Stock Analysis: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$575.79
-3.75 (-0.65%)
▼
5d:
+1.16%
30d:
-0.31%
90d:
+20.93%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Smart Money Distribution
UTHR is up 4.5% this week, but smart money is buying puts. Top strike: $540 2026-06-18 with 337 OI. Put ratio: 83% View Scanner →
Strength: 5.6/10
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: UTHR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: UTHR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$897.19
Based on 10.6% avg growth
INTRINSIC VALUE TODAY
$557.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $575.79, which is considered fair relative to its 30-day fair value range of $567.04 to $581.76. The stock's valuation (Forward PE: 17.9) is in line with its historical norms (17.0). At these levels, the market is pricing in 1.9% annual earnings growth.
Technical Outlook: Technically, UTHR is in a strong uptrend. The price is currently testing key support at $561.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $663.58 (+15.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, UTHR is in a strong uptrend. The price is currently testing key support at $561.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $663.58 (+15.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$567.04 -
$581.76
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
78.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($663.58)
- BULLISH: Expecting earnings turnaround to 1.9% growth with -1.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$567.04 -
$581.76
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$25.44
(4.4%)
Support & Resistance Levels
Support Level
$561.20
Resistance Level
$609.35
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.94
Wall Street Target
$663.58
(+15.2%)
Revenue Growth (YoY)
-1.6%
Earnings Growth (YoY)
-12.2%
Profit Margin
40.6%
Valuation Premium vs History
+1.9% premium
PE vs Historical
17.9 vs 17.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$586.73
(+2%)
2-Year Target
$597.88
(+4%)
3-Year Target
$609.24
(+6%)
3-Yr Target (if PE normalizes)
(PE: 18→17)
PE COMPRESSION
$577.46
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 17.1%)
$1135.61
(+97%)
Base:
(SPY PE: 17.9, Growth: 17.1%)
$924.12
(+61%)
Bear:
(PE: 15.2, Growth: 17.1%)
$785.50
(+36%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 21.42 | Current EPS (TTM): $27.05
Bull Case
$756.59
(+31%)
Analyst growth 18.7%, PE expands to 23.6
Base Case
$687.81
(+20%)
Market implied 18.7%, PE stable at 21.4
Bear Case
$394.09
(-32%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Patusky
SELL
2910 shares
2026-04-24
James Edgemond
SELL
9636 shares
2026-04-23
James Edgemond
SELL
364 shares
2026-04-22
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
